Together, this knowledge on the interaction of plasmin, VWF, and platelets will support the ongoing development of novel therapies98, 99as well as the use of existing thrombolytic therapy to potentially prevent the occurrence of, or degrade, existing VWF–platelet aggregates in conditions such as TTP. This evidence concerns the gene VWF and thrombotic thrombocytopenic purpura.